# Pentavere's Partnership with Takeda to Support Rare Disease

Pentavere tackles gaps in HAE treatment with real-world evidence analysis

"...the use of AI and data analytics to understand the whole of their patient journey to inform diagnosis and best management is a game changer that could prove as impactful as decoding the human genome."

Dr. Durhane Wong-Rieger | CEO, Canadian Organization for Rare Disorders

PENTAVERE

"By harnessing the power of AI and data analytics, and collaborating with experts in these fields, we aim to advance the understanding and management of rare diseases like HAE, supporting patients and their families in their care journey, and ultimately improving patient outcomes."

Jefferson Tea, PhD | VP Medical and Scientific Affairs, Takeda

PENTAVERE

"This collaboration not only underscores the significance of Pentavere's technology, but also highlights the transformative impact data science can have in healthcare. Together, we are breaking new ground in real-world evidence analysis for rare diseases, reaffirming our commitment to driving innovation and improving patient outcomes."

Aaron Leibtag | CEO, Pentavere

PENTAVERE